Progress in site-specific cancer mortality in Canada over the last 70 years.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
03
12
2023
accepted:
01
03
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
7
3
2024
Statut:
epublish
Résumé
In Canada, the absolute number of cancer deaths has been steadily increasing, however, age-standardized cancer mortality rates peaked decades ago for most cancers. The objective of this study was to estimate the reduction in deaths for each cancer type under the scenario where peak mortality rates had remained stable in Canada. Data for this study were obtained the Global Cancer Observatory and Statistics Canada. We estimated age-standardized mortality rates (ASMR, per 100,000) from 1950 to 2022, standardized to the 2011 Canadian standard population. We identified peak mortality rates and applied the age-specific mortality rates from the peak year to the age-specific Canadian population estimates for subsequent years (up to 2022) to estimate the number of expected deaths. Avoided cancer deaths were the difference between the observed and expected number of cancer deaths. There have been major reductions in deaths among cancers related to tobacco consumption and other modifiable lifestyle habits (417,561 stomach; 218,244 colorectal; 186,553 lung; 66,281 cervix; 32,732 head and neck; 27,713 bladder; 22,464 leukemia; 20,428 pancreas; 8863 kidney; 3876 esophagus; 290 liver). There have been 201,979 deaths avoided for female-specific cancers (breast, cervix, ovary, uterus). Overall, there has been a 34% reduction in mortality for lung cancer among males and a 9% reduction among females. There has been a significant reduction in cancer mortality in Canada since site-specific cancer mortality rates peaked decades ago for many cancers. This shows the exceptional progress made in cancer control in Canada due to substantial improvements in prevention, screening, and treatment. This study highlights priority areas where more attention and investment are needed to achieve progress.
Identifiants
pubmed: 38454087
doi: 10.1038/s41598-024-56150-x
pii: 10.1038/s41598-024-56150-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5688Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Brenner, D. R. et al. Projected estimates of cancer in Canada in 2022. CMAJ 194(17), E601–E607 (2022).
doi: 10.1503/cmaj.212097
pubmed: 35500919
pmcid: 9067380
Ervik, M., Lam, F., Laversanne, M., Ferlay, J. & Bray, F. Global Cancer Observatory: Cancer Over Time. International Agency for Research on Cancer; Available from: https://gco.iarc.fr/overtime .
Statistics Canada. Table 17-10-0005-01 Population estimates on July 1st, by age and sex [Data table]. Statistics Canada. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501 (2022).
Statistics Canada. Table 13-10-0142-01 Deaths, by cause, Chapter II: Neoplasms (C00 to D48) [Data table]. Statistics Canada. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310014201 (2022).
Keyfitz, N. Sampling variance of standardized mortality rates. Hum. Biol. 38(3), 309–317 (1966).
pubmed: 5977534
Statistics Canada. Age-standardization: incidence. Available from: https://www.statcan.gc.ca/en/statistical-programs/document/3207_D12_V4#shr-pg0 (2020).
Vandenbroucke, J. P. A shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio. Am. J. Epidemiol. 115(2), 303–304 (1982).
doi: 10.1093/oxfordjournals.aje.a113306
Canada, S. Immigrants make up the largest share of the population in over 150 years and continue to shape who we are as Canadians. Daily 1–21 (2022).
Howson, C. P., Hiyama, T. & Wynder, E. L. The decline in gastric cancer: Epidemiology of an unplanned triumph. Epidemiol. Rev. 8(1), 1–27 (1986).
doi: 10.1093/oxfordjournals.epirev.a036288
pubmed: 3533579
Parsonnet, J. & Forman, D. Helicobacter pylori infection and gastric cancer—for want of more outcomes. JAMA 291(2), 244–245 (2004).
doi: 10.1001/jama.291.2.244
pubmed: 14722152
Evaluation of Carcinogenic Risks to Humans IWG on the, Organization WH, Research on Cancer IA for. Tobacco smoke and involuntary smoking Vol. 83 (IARC, 2004).
University of Waterloo. Historical trends in smoking prevalence. Available from: https://uwaterloo.ca/tobacco-use-canada/adult-tobacco-use/smoking-canada/historical-trends-smoking-prevalence (2022).
Shaw, P. A. The history of cervical screening I: The Pap. test. J. SOGC. 22(2), 110–114 (2000).
doi: 10.1016/S0849-5831(16)31416-1
Popadiuk, C. Cervical cancer screening in Canada. J. Obstet. Gynaecol. 41, S177–S180 (2019).
Dickinson, J. A. et al. Reduced cervical cancer incidence and mortality in Canada: National data from 1932 to 2006. BMC Public Health 12(1), 1–13 (2012).
doi: 10.1186/1471-2458-12-992
Geneva: World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem (2020).
Canadian Partnership against Cancer. Breast cancer screening in Canada: Environmental scan (2018).
Major, D. et al. Colorectal cancer screening in Canada: Results from the first round of screening for five provincial programs. Curr. Oncol. 20(5), 252–257 (2013).
doi: 10.3747/co.20.1646
pubmed: 24155629
pmcid: 3805400
Brenner, D. R. et al. Projected estimates of cancer in Canada in 2020. Cmaj 192(9), E199-205 (2020).
doi: 10.1503/cmaj.191292
pubmed: 32122974
pmcid: 7055947
Statistics Canada. Health Fact Sheets: Cancer Screening, 2017. Available from: https://www150.statcan.gc.ca/n1/pub/82-625-x/2018001/article/54977-eng.htm (2018).
Muggia, F. M., Bonetti, A., Hoeschele, J. D., Rozencweig, M. & Howell, S. B. Platinum antitumor complexes: 50 years since Barnett Rosenberg’s discovery. J. Clin. Oncol. 33(35), 4219–4226 (2015).
doi: 10.1200/JCO.2015.60.7481
pubmed: 26503202
Joy, A., Ghosh, M., Fernandes, R. & Clemons, M. Systemic treatment approaches in her2-negative advanced breast cancer—guidance on the guidelines. Curr. Oncol. 22(s1), 29–42 (2015).
doi: 10.3747/co.22.2360
Brenner, D. R. et al. The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada. Lung Cancer 175, 60–67 (2023).
doi: 10.1016/j.lungcan.2022.11.017
pubmed: 36463730
Brenner, D. R. et al. Editorial: Impact of immunotherapy in lung cancer. Front. Oncol. 12, 1083524 (2022).
doi: 10.3389/fonc.2022.1083524
Ellison, L. F. The cancer survival index: Measuring progress in cancer survival to help evaluate cancer control efforts in Canada. Health Rep. 32(9), 14–26 (2021).
pubmed: 34523870